VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 20.34 Thousand | 23.76 Thousand | 1.16 Million | 1.18 Million | 34.4 Thousand | 34.4 Thousand |
| Selling, General and Administrative Expenses | 20.34 Thousand | 23.76 Thousand | 1.16 Million | 1.18 Million | - | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | 34.4 Thousand | 34.4 Thousand |
| Cost and Expenses | 20.34 Thousand | 23.76 Thousand | 1.16 Million | 1.18 Million | 34.4 Thousand | 34.4 Thousand |
| Operating Income | -20.34 Thousand | -23.76 Thousand | -1.16 Million | -1.18 Million | 34.4 Thousand | 34.4 Thousand |
| Interest Expense | 68.31 Thousand | 49.83 Thousand | 75.71 Thousand | 268.43 Thousand | 302.84 Thousand | 302.84 Thousand |
| Income Tax Expense | -167.89 Thousand | -228.48 Thousand | -236.55 Thousand | -206.29 Thousand | -34.4 Thousand | -34.4 Thousand |
| Earnings before Tax | -2.53 Million | 2.11 Million | -1.24 Million | -1.45 Million | -302.84 Thousand | -302.84 Thousand |
| Net Income | -2.53 Million | 2.11 Million | -1.24 Million | -1.45 Million | -268.43 Thousand | -268.43 Thousand |
| Earnings Per Share Basic | -0.00 | 0.00 | -0.00 | -0.01 | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | 0.00 | -0.00 | -0.01 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 18.7 Billion | 10.93 Billion | 1.2 Billion | 164.5 Million | 129.92 Million | 129.92 Million |
| Weighted Average Shares Outstanding (Diluted) | 18.7 Billion | 10.93 Billion | 1.2 Billion | 164.5 Million | 129.92 Million | 129.92 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -2.46 Million | 2.16 Million | -1.16 Million | -1.18 Million | 34.4 Thousand | 34.4 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 2752.00 | 6237.00 | 20.34 Thousand | 5660.00 | 1700.00 | 8910.00 |
| Selling, General and Administrative Expenses | 2752.00 | 6237.00 | - | 5660.00 | 1700.00 | 8910.00 |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 2752.00 | 6237.00 | 20.34 Thousand | 5660.00 | 1700.00 | 8910.00 |
| Operating Income | -2752.00 | -6240.00 | -20.34 Thousand | -5660.00 | -1700.00 | -8910.00 |
| Interest Expense | 14.44 Thousand | 15.29 Thousand | 68.31 Thousand | 56.86 Thousand | 417.00 | 10.03 Thousand |
| Income Tax Expense | - | -43.27 Thousand | -167.89 Thousand | -43.81 Thousand | 39.58 Thousand | -122.08 Thousand |
| Earnings before Tax | -17.64 Thousand | 2.42 Million | -2.53 Million | -2.5 Million | -3234.00 | -6453.00 |
| Net Income | -17.64 Thousand | 2.42 Million | -2.53 Million | -2.5 Million | -3234.00 | -6453.00 |
| Earnings Per Share Basic | - | 0.00 | - | -0.00 | - | - |
| Earnings Per Share Diluted | - | 0.00 | - | -0.00 | - | - |
| Weighted Average Shares Outstanding | 21.09 Billion | 21.09 Billion | 18.7 Billion | 21.09 Billion | 18.7 Billion | 17.46 Billion |
| Weighted Average Shares Outstanding (Diluted) | 21.09 Billion | 21.09 Billion | 18.7 Billion | 21.09 Billion | 18.7 Billion | 17.46 Billion |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -3195.00 | -6240.00 | - | -5660.00 | -1700.00 | -8910.00 |
| Earnings Before Tax Margin | - | - | - | - | - | - |
4886
TELDF
ACGI
0LQQ
DRCT
ULTJ